Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Blueprint Medicines Corp shares valued at $227,304 were sold by Haviland Kate on Nov 29 ’24. At $96.60 per share, Haviland Kate sold 2,353 shares. The insider’s holdings dropped to 150,824 shares worth approximately $14.34 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Rossi Christina sold 2,274 shares, netting a total of over 216,257 in proceeds. Following the sale of shares at $95.10 each, the insider now holds 71,657 shares.
Before that, KATHRYN D HAVILAND had added 3,799 shares to its account. In a trade valued at $361,285, the Officer bought Blueprint Medicines Corp shares for $95.10 each.
As published in their initiating research note from JP Morgan on November 14, 2024, Blueprint Medicines Corp [BPMC] has been an Overweight and the price target has been revised to $126. Analysts at UBS started covering the stock with ‘”a Neutral”‘ outlook in a report released in late October. As of May 14, 2024, Stephens has initiated its “an Overweight” rating for BPMC. Earlier on May 06, 2024, Leerink Partners upgraded its rating. Their new recommendation was “a Market perform” for BPMC stock which previously was a “an Underperform”.
Analyzing BPMC Stock Performance
During the last five days, there has been a drop of approximately -0.02%. Over the course of the year, Blueprint Medicines Corp shares have jumped approximately 3.08%. Shares of the company reached a 52-week high of $121.90 on 07/16/24 and a 52-week low of $72.24 on 02/14/24. A 50-day SMA is recorded $91.43, while a 200-day SMA reached $96.63. Nevertheless, trading volume fell to 0.75 million shares from 0.52 million shares the previous day.
Support And Resistance Levels for Blueprint Medicines Corp (BPMC)
According to the 24-hour chart, there is a support level at 93.82, which, if violated, would cause prices to drop to 92.55. In the upper region, resistance lies at 96.44. The next price resistance is at 97.79. RSI (Relative Strength Index) is 52.29 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 1.42, which suggests the price will increase in the coming days. Percent R is at 32.66%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
